FHI 360 is a global leader in cutting-edge HIV prevention research, connecting research to practice, which includes generating evidence on the safety and effectiveness of drugs and other HIV prevention technologies.
FHI 360 serves as the Coordinating and Operations Center for the HIV Prevention Trials Network (HPTN). HPTN is a worldwide collaborative clinical trials network that develops and tests the safety and efficacy of interventions designed to prevent the transmission of HIV.
Through the Optimizing Prevention Technology Introduction on Schedule (OPTIONS) consortium, FHI 360 advances the consortium’s goal of providing targeted support to expedite and sustain access to antiretroviral-based HIV prevention products in countries and among populations where most needed. The OPTIONS consortium represents an international, multidisciplinary partnership of global, regional and country experts across the antiretroviral-based HIV prevention research-to-rollout continuum.